Additional Study Information: The purpose of this study is to determine if the administration of non-absorbable antibiotics (rifaximin) for the first three months after liver transplant period will reduce the amount of fibrosis (scarring of the liver) in liver transplant patients with hepatitis C virus (HCV) by lowering serum LPS (a protein in the blood that comes from the bacteria in your intestines and may cause scarring in the liver). Participants will be assigned to receive rifaximin (a tablet) or a placebo (does not contact active study medication) twice daily every day for 3 months post liver transplant.